Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | C-CAR039 |
| Synonyms | |
| Therapy Description |
C-CAR039 is a chimeric antigen receptor T cell (CAR-T) therapy that targets CD19 and CD20, potentially resulting in a decrease in tumor cells (J Clin Oncol 39, no. 15_suppl (May 20, 2021) 2507). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| C-CAR039 | JNJ-90014496|JNJ90014496 | CD19 Immune Cell Therapy 72 CD20 Immune Cell Therapy 14 | C-CAR039 is a chimeric antigen receptor T cell (CAR-T) therapy that targets CD19 and CD20, potentially resulting in a decrease in tumor cells (J Clin Oncol 39, no. 15_suppl (May 20, 2021) 2507). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT05421663 | Phase Ib/II | C-CAR039 | A Study of JNJ-90014496 in Participants With B-Cell Non-Hodgkin Lymphoma | Recruiting | USA | NLD | GBR | ESP | DNK | CAN | AUS | 1 |